NCT03925727: A trial that was reported late by Mimetogen Pharmaceuticals USA, Inc.
This trial has reported, although it was 608 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03925727 |
|---|---|
| Title | Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2019 |
| Completion date | June 11, 2020 |
| Required reporting date | June 11, 2021, midnight |
| Actual reporting date | Feb. 9, 2023 |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | 608 |